Sangamo Biosciences (SGMO) Reports Q2 Loss of $0.17/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Stryker invests $400M in CMR Surgical with option to acquire
- Cerebras Systems hits new 52-week low on unlock concerns
- Enovix posts $11M in Q3 revenue, beats guidance by 10%
Sangamo Therapeutics Reports Second Quarter 2017 Financial Results
August 9, 2017 4:01 PM EDTRICHMOND, Calif., Aug. 9, 2017 /PRNewswire/ --Â Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported its second quarter 2017 financial results and recent accomplishments.
"In the second quarter we strengthened our balance sheet in order to position Sangamo... More



